Overview
Location
United States, Massachusetts, Cambridge
Employees
51-200
Total raised
$215.5M
Founded date
2018
Investors 6
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 17, 2021 | ARCH Venture Partners | archventure.com |
| F-Prime Capital Partners | fprimecapital.com | |
| RA Capital Management | racap.com | |
| Eight Roads | eightroads.com | |
| GV | gv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jun 12, 2020 | Funding round | $63M | |
| May 7, 2019 | Series A round | $58.5M | GV |
Mentions in press and media 28
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 24, 2025 | GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics | Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL,... |
| Nov 24, 2025 | ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics | Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL,... |
| Jun 18, 2025 | Indexes end lower as Israel-Iran fighting raises investor anxiety | Indexes end lower as Israel-Iran fighting raises investor anxiety By Caroline ValetkevitchJune 17, 20259:07 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link FILE PHOTO; Traders work on the floor ... |
| Jun 17, 2025 | Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why | |
| Jun 17, 2025 | Stocks making the biggest moves midday: Jabil, JetBlue, Sunrun, Valero, Verve Therapeutics and more | |
| Dec 19, 2022 | How a gene-editing breakthrough from a Harvard lab saved the life of a girl with leukemia | Alyssa, 13, was the first patient to receive a base-edited cell therapy to treat her leukemia in May 2022. Great Ormond Street Hospital for Children A 13-year-old girl was the world's first patient to get a cell therapy called base editing ... |
| Oct 12, 2022 | Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn | Marianne Ayala/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Redeem now A handful of biotechs specializing in gene editing are charging ahead despite an industry downturn. Inste... |
| May 10, 2022 | Verve gets New Zealand clearance to test base editing therapy directly in the human body | Two years ago, Intellia and Editas Medicine ventured into the field of science fiction when the biotechs directly edited genes in humans. Now, following behind those two companies, which have reported limited data th... |
| Nov 10, 2021 | Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results | VERVE-101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent, Durable PCSK9 Protein and LDL-C Reductions, Supporting Planned Clinical Initiation in 2022 New Preclinical Data from ANGPTL3 Program Highlight Potent Editing with Propr... |
Show more
Reviews 0
FAQ about Verve Therapeutics
When was Verve Therapeutics founded?
Verve Therapeutics was founded in 2018.
How much funding has Verve Therapeutics raised?
Verve Therapeutics has raised $215.5M in total across 3 funding rounds.
What funding rounds has Verve Therapeutics raised?
Parsers VC lists 3 funding rounds of Verve Therapeutics, among them a funding round of $63M on Jun 12, 2020 and a Series A round of $58.5M on May 7, 2019.
Who has invested in Verve Therapeutics?
Parsers VC lists 6 investors of Verve Therapeutics, among them ARCH Venture Partners, F-Prime Capital Partners and RA Capital Management.
What has the press written about Verve Therapeutics?
Parsers VC has collected 28 articles mentioning Verve Therapeutics, among them “GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics” (Nov 24, 2025) and “ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics” (Nov 24, 2025).
Is Verve Therapeutics still active?
Yes, Verve Therapeutics is active; its latest activity on Parsers VC dates from Feb 20, 2026.